首页|衰弱评估及其在老年多发性骨髓瘤中的应用研究进展

衰弱评估及其在老年多发性骨髓瘤中的应用研究进展

扫码查看
多发性骨髓瘤(multiple myeloma,MM)是一种好发于中老年患者的血液系统恶性肿瘤,由于衰弱、合并症的存在,导致老年群体高度异质,呈现出不同的耐受性和治疗获益情况,对老年多发性骨髓瘤的治疗造成了极大地挑战,目前认为通过衰弱性评估对老年患者进行风险分层是实现个体化治疗的主要策略,然而国内老年多发性骨髓瘤中衰弱评估模型尚未建立,老年、衰弱患者的定义及通过衰弱评估工具指导治疗的意见尚不统一,该文就全球对老年、衰弱患者的定义,多发性骨髓瘤中衰弱评估工具及其指导治疗的研究进展作一综述。
Research progress in frailty assessment of elderly multiple myeloma
Multiple myeloma(MM)is a malignant tumor of blood system that occurs in middle-aged and elderly patients.Because of frailty and complications,the elderly population is highly heterogeneous,showing different toler-ance and ability to benefit from treatment,which poses a great challenge to the treatment of elderly multiple myeloma.At present,it is considered that the risk stratification of elderly patients through frailty assessment is the main strategy to realize individualized treatment.However,the frailty assessment model of elderly multiple myeloma in China has not yet been established.The definitions of elderly and frail patients and the opinions of guiding treatment with frailty as-sessment tools are still not uniform.This article reviews the global definitions of elderly and frail patients,the research progress of frailty assessment tools in multiple myeloma and their guiding treatment.

multiple myelomafrailtygeriatric assessment

李玉军、成雨达、肖娟娟、薛华

展开 >

河北大学附属医院血液内科 河北保定 071000

河北大学附属医院心内科,河北保定 071000

多发性骨髓瘤 衰弱 老年评估

2025

现代肿瘤医学
中国抗癌协会 陕西省抗癌协会 陕西省肿瘤防治研究所 陕西省医学会

现代肿瘤医学

影响因子:0.914
ISSN:1672-4992
年,卷(期):2025.33(1)